|
4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone |
|---|---|
| Trade Name | |
| Orphan Indication | Hepatocellular Carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 2007-08-22 00:00:00 |
| Sponsor | Ligand Pharmaceuticals, Inc.;11085 N. Torrey Pines Road, Suite 300;LaJolla, California, 92037 |
